Survodutide: No CV Safety Signal, but 1 in 5 Stopped Treatment

What was announced on November 9, 2026

Boehringer Ingelheim and Zealand Pharma announced the results of SYNCHRONIZE-CVOT, presented at the American Heart Association Scientific Sessions 2026 (Chicago, November 6–9) and published simultaneously in The Lancet¹²⁴. According to AJMC, the phase 3, double-blind, event-driven trial enrolled 5,530 adults with overweight or obesity and established cardiovascular disease, chronic kidney disease, or at least two weight-related complications or risk factors¹².

Participants received weekly survodutide 3.6 mg or 6.0 mg, or placebo¹. Survodutide is a dual agonist of the glucagon and GLP-1 receptors, still investigational and not approved for any use¹²¹⁰.

The primary endpoint numbers: noninferiority

The primary endpoint was time to first event of an adjudicated 5-point composite of major adverse cardiovascular events (5-point MACE)¹⁵. Survodutide was noninferior to placebo: HR 0.89 (95% CI 0.67–1.18; P < .001 for noninferiority, treatment-regimen estimand)¹. The key secondary endpoint, 3-point MACE (cardiovascular death, nonfatal MI or nonfatal stroke), gave HR 0.84 (95% CI 0.60–1.18)¹².

Noninferiority is not benefit

Both confidence intervals cross 1. Company releases and trade press frame this as a safety result: survodutide did not increase major adverse cardiovascular events vs placebo¹²³. It does not show that it reduces them. The sources we reviewed do not state the prespecified noninferiority margin, a detail worth checking in the full Lancet paper, which we could not open at the time of writing.

The distinction matters because there is a benchmark. In SELECT, 17,604 adults with cardiovascular disease and overweight or obesity without diabetes, semaglutide 2.4 mg weekly reduced the composite of cardiovascular death, nonfatal MI or nonfatal stroke: 6.5% vs 8.0% with placebo (HR 0.80; 95% CI 0.72–0.90)¹¹. In SURPASS-CVOT, tirzepatide was noninferior to dulaglutide in type 2 diabetes with atherosclerotic cardiovascular disease (HR 0.92; 95% CI 0.83–1.01; P = 0.003 for noninferiority; P = 0.09 for superiority)¹². Populations, comparators and designs differ, so the numbers should not be compared head to head.

The secondary cardiometabolic effects

At 72 weeks, per the supplementary secondary estimand, systolic blood pressure fell by up to 6.68 mmHg with survodutide vs 1.76 mmHg with placebo (P = .0001); waist circumference by up to 11.96 cm vs 2.74 cm; and body weight by up to 13.7% vs 2.0%, in a population that included people with type 2 diabetes¹². High-sensitivity C-reactive protein and triglycerides also fell significantly¹². These figures come from an analysis that assumes no intercurrent events (the effect in people who stay on treatment), so they tend to look more favorable than the treatment-regimen analysis².

Tolerability: 1 in 5 stopped for GI symptoms

The most common adverse events were gastrointestinal (nausea, vomiting, diarrhea and constipation), mostly mild to moderate¹². Even so, 19.3% on 3.6 mg and 20.8% on 6.0 mg stopped treatment for that reason, vs 1.9% on placebo¹²³. According to the companies, most discontinuations occurred during dose escalation, and the original protocol allowed limited flexibility to titrate, adjust or pause¹².

This is not unique to this trial. In SYNCHRONIZE-1 (obesity without diabetes, 76 weeks), gastrointestinal symptoms, typically mild to moderate, occurred in 80.9% (3.6 mg) and 89.7% (6.0 mg) of participants vs 47.9% with placebo⁶. In SYNCHRONIZE-2, in adults with obesity and type 2 diabetes, GI-related discontinuation was 18% vs 1.2% with placebo, with weight loss of up to 13.1% at 76 weeks vs 3.1%⁷⁸. In phase 2, adverse events were primarily gastrointestinal in 75% of survodutide recipients vs 42% on placebo⁹. In SELECT, adverse events leading to permanent discontinuation were 16.6% with semaglutide vs 8.2% with placebo; that is a broader measure than GI alone, so it is not directly comparable either¹¹. Later phase 3b studies are testing more flexible titration; SYNCHRONIZE-START, for example, looks at starting treatment and switching from other GLP-1 agonists².

What the glucagon component adds

The mechanistic hypothesis is that GLP-1 agonism reduces food intake while glucagon receptor agonism adds effects on energy expenditure and hepatic metabolism¹⁰. Survodutide also holds FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis². A 2026 review notes that its comparative effectiveness, durability and long-term safety remain to be established¹⁰; an earlier review asked where the "sweet spot" for glucagon-based therapy lies¹⁵. A cardiovascular safety trial with no signal is an important piece of that puzzle, but it does not complete it: long-term follow-up and head-to-head comparison with other incretin drugs are still pending.

What comes next: regulation and the gray market

Boehringer Ingelheim said it is moving ahead with global regulatory submissions in obesity, without giving dates, and that the registrational SYNCHRONIZE phase 3 program is complete². Until a regulator approves it, survodutide remains an investigational drug. On its page on unapproved GLP-1 drugs, the FDA lists survodutide among products sold with the false label "for research purposes" or "not for human consumption", marketed directly to consumers with dosing instructions, and describes them as "of unknown quality"¹⁴. For market and regulatory context, see our analysis of FDA warning letters and of the new generation of obesity drugs. From the same multi-receptor family, retatrutide (a triple agonist) showed −25.0% body weight at the 12 mg dose in TRIUMPH-1, but it is not approved either¹³.